Rainforest plant shows promise in fighting COVID-19 through multitarget mechanism

At a glance:

• Scientists discovered that Copaifera lucens, a plant from Brazil's Mata Atlantica rainforest, contains compounds that neutralize COVID-19 through a unique multitarget mechanism
• The galloylquinic acids found in the plant inhibit COVID-19's spike proteins and enzymes while also showing effectiveness against HIV-1
• Brazil's biodiversity, including this discovery, highlights the nation's importance in global pharmaceutical research amid its zero deforestation efforts

The Discovery in Brazil's Biodiversity Hotspot

Brazil stands as the world's leading "mega-biodiverse" nation according to the United Nations, hosting approximately 55,000 unique plant species. While often associated with the Amazon rainforest, which covers 60% of Brazil's territory, the nation's ecological richness extends significantly to the Mata Atlantica along its eastern coast. It was in this lesser-known rainforest that an international team of biologists, immunologists, and pharmaceutical chemists made a significant discovery earlier this year. They identified that leaves of Copaifera lucens Dwyer, a tree endemic to the Mata Atlantica region, contain chemical compounds capable of neutralizing COVID-19 through a "multitarget mode of action" that disables the virus's spike proteins and enzymes.

The research team, led by pharmacist Jairo Kenupp Bastos from the Ribeirão Preto School of Pharmaceutical Sciences at the University of São Paulo (FCFRP-USP), emphasized the importance of this discovery's mechanism. "Many current antivirals act on only one viral protein," Bastos explained in a statement. "An important aspect revealed by this information is the multi-target mechanism of the compound, which reduces the likelihood of resistance developing." This multitarget approach represents a significant advantage over many existing treatments, as it makes it more difficult for the virus to develop resistance through mutation, potentially slowing the impact of future COVID-19 variants.

The Science Behind the Plant's Effectiveness

The compounds responsible for this antiviral activity are galloylquinic acids, a subset of tannins—a class of astringent biochemicals also found in tea leaves and red wine. Through extensive laboratory analysis, the researchers identified six distinct subcategories of galloylquinic acid within the Copaifera lucens plant, using ultraviolet spectroscopy methods on specially treated leaf samples. One particular molecular configuration, 3,4,5-tri-galloylquinic acid, demonstrated a "strong binding affinity" with the receptor binding domains of COVID-19's spike protein, the critical protrusion that allows the virus to attach to human cells.

Further testing using plaque reduction neutralization assays—considered the "gold standard" for antiviral testing—revealed that these galloylquinic acids also neutralize COVID-19's papain-like protease enzyme, which helps the virus evade immune responses, as well as RNA polymerase, an enzyme essential to viral replication. "This integrated approach allowed us to understand how the compounds work and how they act at the molecular level," explained Mohamed Abdelsalam, a study coauthor and assistant professor with the Delta University of Science and Technology in Egypt. The comprehensive nature of these tests provides strong preliminary evidence for the plant's potential therapeutic value against COVID-19.

Broader Antiviral Properties and Implications

The effectiveness of galloylquinic acids extends beyond COVID-19, with the research also demonstrating inhibition of HIV-1 among other antiviral and antifungal properties. This broad-spectrum potential makes the discovery particularly significant in the ongoing search for treatments against multiple viral threats. The researchers noted that the multitarget mechanism not only combats existing viruses but may also provide protection against future variants that might otherwise develop resistance to single-target treatments.

The significance of this discovery extends beyond the laboratory. The São Paulo Research Foundation, which helped fund the research, highlighted that the project underscores Brazil's biodiversity as both an economic asset and a global public health resource. "A few more steps remain before the substance can be developed into a drug against COVID-19, including in vivo and clinical trials," the foundation acknowledged. "However, the study … also reinforces the idea that Brazilian flora is a rich and strategic source for discovering new drugs." This perspective connects the scientific discovery to broader conservation efforts and the economic value of preserving natural ecosystems.

Brazil's Conservation Context

Brazil's biodiversity exists within a complex conservation landscape. President Luiz Inácio Lula da Silva, elected in 2022 on a platform promising net "zero deforestation," has made notable progress in protecting the Amazon. According to Global Forest Watch, deforestation in the Brazilian Amazon decreased by 36% during Lula's first year back in office. These gains occurred despite significant challenges, including record wildfires that burned an area larger than Italy in 2024, civil servant strikes, and persistent black market economies built on illegal land grabs, logging, and mining.

The discovery of Copaifera lucens's potential benefits adds another dimension to the conservation debate. As the São Paulo Research Foundation noted, Brazil's flora represents not just an ecological treasure but a strategic resource for global health. This creates a compelling argument for conservation efforts that emphasize both environmental protection and the preservation of potential medical resources. The connection between biodiversity conservation and pharmaceutical development underscores the importance of maintaining healthy ecosystems for future medical breakthroughs.

Path to Clinical Application

While the laboratory results are promising, translating the discovery from the rainforest to the pharmacy requires several additional steps. The galloylquinic acids must undergo further testing, including in vivo studies (in living organisms) and eventually clinical trials in humans. These subsequent phases will determine the safety, efficacy, and appropriate dosage levels for potential treatments derived from the plant compounds.

The research team has identified specific molecular configurations that show particular promise, such as 3,4,5-tri-galloylquinic acid, which demonstrated strong binding with COVID-19's spike protein. However, developing these compounds into marketable drugs involves additional considerations, including formulation, delivery methods, and potential side effects. The multitarget mechanism that makes these compounds attractive also presents challenges in standardization and regulatory approval, as multiple pathways of action require comprehensive evaluation.

Global Health Implications

The discovery highlights the critical connection between biodiversity and public health on a global scale. As COVID-19 demonstrated, viral threats can emerge and spread rapidly across international borders, making research into potential treatments a global priority. The identification of effective compounds in a relatively obscure Brazilian plant underscores the importance of continued exploration of natural products for pharmaceutical development.

This research also emphasizes the value of international scientific collaboration. The project involved researchers from Brazil and Egypt, demonstrating how global partnerships can accelerate discovery and development. As the world faces ongoing health challenges, the combination of traditional knowledge about medicinal plants with modern scientific techniques offers a promising path forward in developing new treatments and preventive measures against infectious diseases.